Atrium Therapeutics, Inc. (RNA)
10.36
-0.15
(-1.43%)
USD |
NASDAQ |
Sep 10, 16:00
10.36
0.00 (0.00%)
After-Hours: 19:17
Atrium Therapeutics Enterprise Value : -82.74M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | -82.74M |
| September 08, 2026 | -68.37M |
| September 04, 2026 | -19.79M |
| September 03, 2026 | -12.78M |
| September 02, 2026 | -22.02M |
| September 01, 2026 | -26.98M |
| August 31, 2026 | -34.68M |
| August 28, 2026 | -29.20M |
| August 27, 2026 | -23.39M |
| August 26, 2026 | -25.61M |
| August 25, 2026 | -23.04M |
| August 24, 2026 | -29.54M |
| August 21, 2026 | -36.73M |
| August 20, 2026 | -31.94M |
| August 19, 2026 | -28.00M |
| August 18, 2026 | -42.89M |
| August 17, 2026 | -40.83M |
| August 14, 2026 | -42.89M |
| August 13, 2026 | -51.61M |
| August 12, 2026 | -54.35M |
| August 11, 2026 | -52.64M |
| August 10, 2026 | -53.15M |
| August 07, 2026 | -51.44M |
| August 06, 2026 | -55.37M |
| August 05, 2026 | -61.70M |
| Date | Value |
|---|---|
| August 04, 2026 | -65.12M |
| August 03, 2026 | -68.72M |
| July 31, 2026 | -68.37M |
| July 30, 2026 | -66.49M |
| July 29, 2026 | -71.28M |
| July 28, 2026 | -65.98M |
| July 27, 2026 | -64.61M |
| July 24, 2026 | -65.98M |
| July 23, 2026 | -58.80M |
| July 22, 2026 | -54.35M |
| July 21, 2026 | -52.30M |
| July 20, 2026 | -61.36M |
| July 17, 2026 | -54.69M |
| July 16, 2026 | -54.52M |
| July 15, 2026 | -52.12M |
| July 14, 2026 | -53.49M |
| July 13, 2026 | -53.49M |
| July 10, 2026 | -49.39M |
| July 09, 2026 | -41.69M |
| July 08, 2026 | -33.82M |
| July 07, 2026 | -36.04M |
| July 06, 2026 | -39.98M |
| July 02, 2026 | -29.03M |
| July 01, 2026 | -35.02M |
| June 30, 2026 | -32.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -49.92M |
| Exicure, Inc. | 7.398M |
| Century Therapeutics, Inc. | 285.47M |
| Absci Corp. | 1.287B |
| Celularity, Inc. | 110.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.19M |
| Revenue (Quarterly) | 3.004M |
| Total Expenses (Quarterly) | 23.19M |
| EPS Diluted (Quarterly) | -1.18 |
| Gross Profit Margin (Quarterly) | 88.58% |
| Profit Margin (Quarterly) | -672.0% |
| Earnings Yield | -44.48% |
| Normalized Earnings Yield | -44.48 |